Generic consolidation
The race is on. For a change, all action in the global pharmaceutical industry appears to be focussed on the generics front in recent times. This is not to say that research, NCEs and scientific breakthroughs have been relegated to the backburners.

A case for lower dose of rosuvastatin
Unless ongoing trial results lead to a different conclusion, the use of 40mg and 20mg should be as restricted in Asian patients as it may be bioequivalent to a dose of 80mg and 40mg in Caucasians, says Dr Krishan Maggon